Outcome of Board meeting held on 13.11.2025

Net loss reportedNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-7.8%Reaction day

₹27.85

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-7.7% vs market

Healthcare Service Provider peers, median of 23sector-0.2%-7.6% vs sector

On the reaction day the stock moved 7.7 pts less than Nifty Microcap 250 and 7.6 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-7.8-0.1-7.7-0.2-7.6

Next day

-12.9+0.5-13.4-0.1-12.9

-7.0-0.3-6.7-1.8-5.2

-5.1-0.5-4.6-1.2-3.9

-0.3-0.8+0.5-1.8+1.6

+3.1-2.3+5.4-0.7+3.8

+0.5-2.8+3.3-2.2+2.7

15d

+24.8-4.9+29.7-6.8+31.6

+9.4-4.7+14.2-7.7+17.1

+4.2-7.7+11.9-10.3+14.5

+11.9-7.8+19.7-13.7+25.6

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 23Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board approved unaudited financial results for the quarter and half-year ended 30 September 2025. Standalone numbers show severe distress: Q2 revenue collapsed to Rs. 32.93 lakhs from Rs. 316.61 lakhs a year ago (~90% decline) and the company posted a standalone net loss of Rs. 34.74 lakhs in Q2 (vs profit of Rs. 33.08 lakhs last year). H1 standalone loss widened to Rs. 61.63 lakhs, and standalone other equity has turned negative at Rs. (51.34) lakhs vs Rs. 10.25 lakhs at March 2025. Cash flow from operations was negative Rs. 17.61 lakhs (H1 standalone). Consolidated numbers look far healthier because subsidiary VSR Paper & Packaging (55% holding) is the real driver – Q2 consolidated revenue jumped ~51% YoY to Rs. 1,222.83 lakhs and Q2 PAT rose sharply to Rs. 14 lakhs, though H1 consolidated PAT actually fell to Rs. 6.02 lakhs vs Rs. 67.19 lakhs. Auditor M M Reddy & Co. issued an unqualified limited review report on both sets of results.

Likely market impact

Standalone pharma business is in clear trouble with shrinking top line, losses and negative net worth — minority shareholders effectively depend entirely on the paper packaging subsidiary. Consolidated total borrowings (~Rs. 2,189 lakhs) against equity of ~Rs. 1,593 lakhs mean the group is also fairly leveraged, so any further slowdown in the subsidiary could weigh on the stock. Near-term, the headline deterioration in standalone results is the main negative signal for investors.